Generic Soriatane ( Acitretin )

Order cheap Generic Soriatane (Acitretin) without dr prescription in the United States

In our USA pharmacy, you can buy Soriatane without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Soriatane (acitretin) is an oral retinoid—a synthetic derivative of vitamin A—used to treat severe plaque psoriasis and other disorders of keratinization. It works by binding to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), normalizing the growth and differentiation of skin cells, reducing inflammation, and slowing the excessive production of skin cells that causes psoriatic plaques.
Usual adult dose: The recommended starting dose is 25 mg to 50 mg once daily, taken with the main meal. After 4 weeks the dose may be adjusted based on response and tolerability; typical maintenance doses are 25 mg to 50 mg daily, with a maximum of 75 mg per day. Lower doses (e.g., 10 mg daily) may be used for keratinization disorders or as maintenance in patients who respond well to low‑dose therapy.
Dosage form: Capsules for oral administration (10 mg, 17.5 mg, 22.5 mg, 25 mg).
Onset of action: 8 to 16 weeks for full therapeutic effect on psoriasis; initial improvement may be seen within 2 to 4 weeks.
Duration of action: Once‑daily dosing maintains steady clinical benefit; relapse occurs within weeks to months after discontinuation.
Alcohol consumption must be strictly avoided during treatment and for 2 months after stopping therapy in all patients, especially women of childbearing potential, because ethanol converts acitretin to etretinate (a retinoid with a much longer half‑life and teratogenic potential).
Most common side effects: dry lips (cheilitis), dry skin, peeling skin, alopecia (hair thinning), dry eyes, and dry mouth.
Would you like to try Soriatane without a prescription?

General Information about Soriatane

• INN (International Nonproprietary Name): Acitretin
• Brand names available in the USA: Soriatane® (brand originally marketed by Stiefel Laboratories; brand capsules discontinued; multiple FDA‑approved generic versions available). Generic manufacturers include Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Alembic Pharmaceuticals, Barr Laboratories, Impax Laboratories, Sigmapharm Laboratories, and Amneal Pharmaceuticals of New York LLC.
• ATC code: D05BB02
• Dosage forms and strengths: Hard gelatin capsules containing 10 mg, 17.5 mg, 22.5 mg, or 25 mg of acitretin.
• Manufacturers in USA: Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Alembic Pharmaceuticals; Amneal Pharmaceuticals of New York LLC; Barr Laboratories; Impax Laboratories; Sigmapharm Laboratories.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) (NDA 019821, 1996).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Acitretin is a second‑generation aromatic retinoid and the free‑acid metabolite of etretinate. It freely accesses the intracellular space and binds to all three subtypes of nuclear retinoic acid receptors (RAR‑α, RAR‑β, RAR‑γ) and retinoid X receptors (RXRs). These ligand‑activated transcription factors modulate the expression of genes that regulate cell proliferation, differentiation, inflammation, and keratinization. In psoriasis, acitretin normalizes keratinocyte differentiation, reduces epidermal thickness, decreases the expression of inflammatory mediators, and inhibits neutrophil chemotaxis. Unlike etretinate, acitretin is relatively water‑soluble, has a much shorter elimination half‑life (approximately 49 hours for acitretin versus 100–120 days for etretinate), and does not extensively accumulate in adipose tissue. It is highly protein‑bound (>99%) and is metabolized by isomerization and glucuronidation. Excretion occurs primarily via the kidneys and bile. Oral bioavailability is approximately 60% and increases significantly when taken with a high‑fat meal.

Indications

• Treatment of severe plaque‑type psoriasis (including erythrodermic and generalized pustular psoriasis) that is unresponsive to topical therapies or phototherapy.
• Combination therapy with ultraviolet B (UVB) phototherapy or psoralen plus ultraviolet A (PUVA) photochemotherapy to enhance efficacy and reduce cumulative light doses.
• Combination therapy with cyclosporine or biologic therapies (e.g., TNF‑alpha inhibitors) in refractory cases.
• Off‑label uses: Darier disease, palmoplantar pustulosis, lichen planus, severe ichthyosis, Sjögren–Larsson syndrome, pityriasis rubra pilaris, lupus erythematosus, and chemoprevention of non‑melanoma skin cancers in high‑risk patients (e.g., solid organ transplant recipients).

Important Warnings and Precautions

SORIATANE CARRIES A BOXED WARNING FOR TERATOGENICITY. Acitretin causes severe, life‑threatening birth defects and must NEVER be used during pregnancy. Females of childbearing potential must use two effective forms of contraception simultaneously for at least 1 month before, during, and for at least 3 YEARS after treatment. Alcohol must be avoided during therapy and for 2 months after discontinuation. Hepatotoxicity including elevations in transaminases and rare cases of acute liver injury have been reported; monitor liver function tests before and during therapy. Hyperlipidemia is common; monitor fasting lipids and manage with diet or lipid‑lowering agents as needed. Pseudotumor cerebri (benign intracranial hypertension) has been reported, especially with concomitant tetracycline or isotretinoin use. Acute pancreatitis may occur secondary to severe hypertriglyceridemia. Skeletal abnormalities (hyperostosis, calcification of ligaments/tendons, premature epiphyseal closure in children) have been associated with long‑term retinoid therapy. Depression, mood changes, and rare cases of suicidal ideation have been reported; monitor for behavioral changes. Photosensitivity is common; avoid excessive sun exposure and use broad‑spectrum sunscreens.

At‑risk groups

• Elderly: No specific dose adjustment is recommended; however, older adults may be more susceptible to hyperlipidemia, hepatotoxicity, and skeletal effects. Monitor closely.
• Pregnancy: ABSOLUTELY CONTRAINDICATED. FDA Pregnancy Category X. Acitretin causes major fetal abnormalities. The pregnancy‑avoidance period extends for 3 full years after stopping therapy.
• Breastfeeding: Contraindicated. Acitretin is excreted in human milk; breastfeeding women must not use this drug.
• Renal impairment: Severe renal impairment is a contraindication due to reduced drug clearance and increased risk of toxicity.
• Hepatic impairment: Severe hepatic impairment is a contraindication. In mild‑to‑moderate impairment, use with extreme caution and intensive monitoring of liver function.
• Pediatric: Safety and efficacy have not been established in children. Use only in exceptional circumstances (e.g., severe ichthyosis) under specialist supervision, with monitoring for skeletal toxicity and premature epiphyseal closure.
• Diabetes: Acitretin can impair glucose tolerance; monitor blood glucose levels closely.
• Concomitant retinoids: Do not use with other systemic retinoids (e.g., isotretinoin, tretinoin) due to additive toxicity.

Driving and alcohol

Acitretin may cause visual disturbances, including decreased night vision, which can impair the ability to drive or operate machinery, especially at night. Patients should exercise caution when driving after dark. ALCOHOL IS STRICTLY CONTRAINDICATED in all patients taking acitretin, and women of childbearing age must continue to avoid alcohol for 2 full months after stopping treatment. Ethanol causes transesterification of acitretin to etretinate, a retinoid that can remain in the body for more than 3 years and carries a prolonged teratogenic risk. This alcohol restriction applies to ALL sources of alcohol, including beer, wine, liquor, and alcohol‑containing over‑the‑counter products (e.g., some cough syrups, mouthwashes).

Dosage Instructions

• Psoriasis – initial therapy: 25 mg to 50 mg orally once daily as a single dose with the main meal. Starting at 25 mg may improve tolerability.
• Psoriasis – maintenance: 25 mg to 50 mg once daily, titrated to the lowest effective dose. Maximum dose is 75 mg per day.
• Keratinization disorders (off‑label): Initial dose of 10 mg once daily; may be titrated up to 50 mg daily based on response and tolerability. Some patients may be maintained on less than 10 mg daily long‑term.
• Combination with phototherapy: When used with UVB or PUVA, the dose of acitretin and/or the light dose may need to be reduced based on individual response.
• Administration: Take with the largest meal of the day to enhance absorption. Swallow whole; do not crush or chew.
• Treatment duration: Psoriasis typically improves over 8–16 weeks. Long‑term maintenance may be required to sustain remission. Keratinization disorders may require indefinite therapy.
• Missed dose: Take the missed dose as soon as remembered, unless it is nearly time for the next dose. Do not double the dose.

Side Effects and Contraindications

Common side effects (≥10%): Cheilitis (dry, cracked lips – nearly universal, >90%), dry skin and mucous membranes, skin peeling (especially on palms and soles), alopecia (hair thinning – up to 50%), pruritus, dry eyes, dry mouth, epistaxis (nosebleeds), and hypertriglyceridemia. These effects are dose‑dependent and usually reversible upon dose reduction or discontinuation.
Less common but clinically important: Elevated liver transaminases (ALT/AST), hypercholesterolemia, decreased high‑density lipoprotein (HDL), arthralgia, myalgia, joint pain, skeletal hyperostosis, calcification of ligaments and tendons, photosensitivity, decreased night vision, blurred vision, headache, pseudotumor cerebri (benign intracranial hypertension), mood changes, depression, and aggressive or suicidal thoughts (rare).
Serious adverse reactions: Teratogenicity (severe birth defects), hepatotoxicity including acute hepatitis and jaundice, acute pancreatitis (especially with triglycerides >800 mg/dL), exfoliative dermatitis, and capillary leak syndrome (rare).
Absolute contraindications: Pregnancy or risk of pregnancy within 3 years after treatment; females of childbearing potential who cannot or will not comply with the mandatory two‑form contraception requirement and pregnancy testing program; breastfeeding; known hypersensitivity to acitretin or any excipient; severe hepatic impairment; severe renal impairment; concomitant use with methotrexate (increased hepatotoxicity risk) or tetracyclines (increased intracranial pressure risk); concurrent use of vitamin A or other retinoids; alcohol consumption during and for 2 months after treatment in women of childbearing potential.

Drug Interactions

• Alcohol (ethanol): CONTRAINDICATED – causes transesterification of acitretin to etretinate, extending the teratogenic risk period from approximately 2 months to over 3 years.
• Methotrexate: Contraindicated due to additive hepatotoxicity risk.
• Tetracyclines (doxycycline, minocycline, tetracycline): Contraindicated – increased risk of pseudotumor cerebri (benign intracranial hypertension).
• Vitamin A and other retinoids: Contraindicated – additive toxicity and hypervitaminosis A syndrome.
• Micro‑dosed progestin‑only oral contraceptives (“minipill”): Acitretin interferes with their contraceptive effect; women using acitretin must NOT rely on micro‑dosed progestin preparations as one of their two required birth control methods.
• Phenytoin: Acitretin may reduce phenytoin protein binding; monitor phenytoin levels.
• Glyburide: Acitretin may enhance the glucose‑lowering effect; monitor blood glucose.
• CYP450 interactions: Acitretin may inhibit CYP3A4 and CYP1A1 in vitro; clinical relevance is uncertain, but caution is advised when co‑administering with CYP3A4 substrates (e.g., cyclosporine, midazolam).
• Low‑dose oral contraceptives: Acitretin may reduce the efficacy of some oral contraceptives; women must use two effective forms of contraception simultaneously.

Practical Advice

• Take Soriatane exactly as prescribed, once daily with the main meal to maximize absorption and reduce stomach irritation.
• Never share this medication with anyone else; it is prescribed specifically for your condition.
• Do not donate blood during treatment and for at least 3 years after stopping therapy, as acitretin/etretinate can harm a fetus if transfused into a pregnant woman.
• Women of childbearing potential must enroll in the mandatory pregnancy prevention program, use two effective forms of contraception simultaneously, and undergo monthly pregnancy testing during treatment plus every‑3‑months testing for 3 years after discontinuation.
• Use a moisturizer and lip balm regularly to manage dryness; avoid wearing contact lenses if dry eyes become problematic.
• Avoid excessive sun exposure and use broad‑spectrum sunscreen (SPF 30 or higher) daily, as acitretin increases photosensitivity.
• Do not use tanning beds or sunlamps.
• Regular monitoring of liver function tests, fasting lipid profile, and blood glucose is essential before starting and periodically during treatment.
• Report any of the following to your prescriber promptly: severe or persistent headache, nausea, vomiting, blurred vision, visual disturbances (especially decreased night vision), bone or joint pain, mood changes, depression, suicidal thoughts, abdominal pain (possible pancreatitis), or yellowing of the skin/eyes.
• Store at controlled room temperature (20–25°C / 68–77°F), protect from light and moisture, and keep out of reach of children.
• Do not dispose of unused medication in household waste or wastewater; consult your pharmacist for proper disposal.

Alternative Medications

• Methotrexate: Oral or injectable immunosuppressant; first‑line systemic therapy for moderate‑to‑severe psoriasis; requires monitoring for hepatotoxicity and bone marrow suppression; more rapid onset than acitretin but NOT to be used concurrently.
• Cyclosporine: Calcineurin inhibitor; rapid‑acting systemic immunosuppressant effective in severe psoriasis; limited by nephrotoxicity and hypertension with long‑term use; can be used in combination with acitretin under specialist care.
• Biologic therapies: TNF‑alpha inhibitors (e.g., adalimumab, etanercept, infliximab), IL‑17 inhibitors (e.g., secukinumab, ixekizumab), IL‑23 inhibitors (e.g., guselkumab, risankizumab), and IL‑12/23 inhibitor (ustekinumab); highly effective targeted therapies administered by injection; used in moderate‑to‑severe psoriasis.
• Apremilast (Otezla®): Oral phosphodiesterase‑4 (PDE4) inhibitor; non‑biologic systemic option; lower efficacy than biologics but no requirement for routine laboratory monitoring; also indicated for psoriatic arthritis.
• Deucravacitinib (Sotyktu®): Oral TYK2 inhibitor; once‑daily tablet; novel mechanism of action for moderate‑to‑severe psoriasis.
• Topical therapies: Corticosteroids, vitamin D analogues (calcipotriene), tazarotene (topical retinoid), and calcineurin inhibitors; appropriate for mild disease or as adjuncts to systemic therapy.
• Phototherapy (UVB, PUVA): Narrowband UVB or PUVA photochemotherapy; often used in combination with acitretin to enhance response and reduce cumulative light exposure.

Clinical Efficacy

Acitretin monotherapy has been shown to be effective in the treatment of severe plaque psoriasis, with 50–70% of patients achieving at least a 50% reduction in Psoriasis Area and Severity Index (PASI 50) scores, and 25–40% achieving PASI 75 after 12–16 weeks. It is particularly effective in pustular and erythrodermic variants of psoriasis. When combined with UVB or PUVA phototherapy, acitretin significantly enhances clearance rates while reducing the total ultraviolet light dose required, thereby lowering the long‑term risk of skin cancer. As a chemopreventive agent, long‑term acitretin use in solid organ transplant recipients and other high‑risk populations has been shown to reduce the incidence of squamous cell carcinoma and basal cell carcinoma by up to 50%. Its non‑immunosuppressive mechanism makes it uniquely suitable for use in patients with a history of infections or malignancies, unlike cyclosporine, methotrexate, or biologics. However, acitretin generally has a slower onset of action and lower overall efficacy for chronic plaque psoriasis than the newer biologic agents.

Important:

Soriatane (acitretin) is a potent teratogen and is ABSOLUTELY CONTRAINDICATED in pregnancy. It must be prescribed and supervised by physicians experienced in the use of systemic retinoids for severe psoriasis. Female patients of childbearing potential must comply with the mandatory pregnancy prevention program (T.A.P.P. – Take Action to Prevent Pregnancy), use two effective forms of contraception for at least 1 month before, throughout, and for 3 YEARS after discontinuing therapy, and undergo regular pregnancy testing. Alcohol is STRICTLY PROHIBITED during treatment and for 2 months after cessation in all patients, especially women. Never donate blood during or for 3 years after therapy. This drug is not a first‑line treatment for psoriasis and should be reserved for severe, refractory cases. Do not use with methotrexate or tetracyclines. If you experience severe headache, vision changes, abdominal pain, mood alterations, or suicidal thoughts, seek medical attention immediately. Keep out of reach of children and never share with anyone else.

How to buy Generic Soriatane no prescription U.S. Online Pharmacy